drug · small molecule
RINVOQ
updated 6mo agoby $ABBV AbbVie Inc.🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 5Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for rheumatoid arthritis and 14 investigational indications.
targets
Tyrosine-protein kinase JAK1Tyrosine-protein kinase JAK2Non-receptor tyrosine-protein kinase TYK2Tyrosine-protein kinase JAK3
all catalysts(0)
nothing on the calendar yet
Trials studying RINVOQ
- phase2Platform Study of Targeted Therapies for Adults With Moderately to Severely Active Rheumatoid Arthritis
- phase3A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
- phase3Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
- phase2A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis
- phase3A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata
- —Expanded Access to Upadacitinib
- phase3Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
- phase3A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
News(10)
- AbbVie bets up to $1.47B for Nxera’s discarded IBD programAbbVie’s $100 million upfront cash payment will purchase global rights to Nxera’s deprioritized oral small molecule, which has already completed Phase 1 testing.biospace · 15d ago
- AbbVie pens $1.4B deal for deprioritized IBD drug from NxeraAbbVie has added another angle to its relationship with Nxera, with the Big Pharma paying $100 million upfront for a phase 1 inflammatory bowel disease candidate.fiercebiotech · 15d ago
- AbbVie’s Q3 beat should keep ‘train rolling’ as company eyes bolt-on dealsStrong immunology and neuroscience sales fueled AbbVie’s latest quarterly beat as the pharma’s stock continues to hit all-time highs.biospace · 20d ago
- As AbbVie’s Crohn’s combo beats Skyrizi in mid-stage test, analysts laud autoimmune visionAbbVie’s next-gen dual-targeting therapy elicited higher rates of remission than its IL-23 inhibitor Skyrizi in a Phase 2a trial of Crohn’s disease, leading analysts to wonder if the blockbuster ca…biospace · 1mo ago
- AbbVie’s next-gen Crohn’s disease combo beats Skyrizi in phase 2 trialAbbVie’s next-generation Crohn’s disease combination candidate has beaten Skyrizi in a midphase clinical trial.fiercebiotech · 1mo ago
- Pharma’s $500B patent problem will come in waves — not as a cliffMerck is the most vulnerable to generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and others will also grapple with patent losses in the years to come.biopharma_dive · 1mo ago
- 6 immunology targets to sustain a mammoth I&I marketJohnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and…biospace · 1mo ago
- North Immunology joins biotech reverse merger boom with Aethlon dealArmed with $180 million and a dual-acting antibody for eczema, the startup is capitalizing on a change in sentiment that’s led to a sudden spike in reverse merger deals.biopharma_dive · 2mo ago
- North Immunology goes public via reverse merger as eczema drug heads toward clinicNorth Immunology has decided its path to taking an atopic dermatitis drug into the clinic involves going public via a reverse merger.fiercebiotech · 2mo ago
- Spyre's 3-pronged IBD strategy on track as IL-23 antibody rounds off trio of phase 2 winsSpyre's three-pronged approach to inflammatory bowel disease continues to pay off, with the biotech's anti-IL-23 antibody notching a phase 2 win.fiercebiotech · 2mo ago
Data sources
last refreshed 7h ago
Found something off?
comments(0)
5-min edit window · permanent after that